Colon cancer is still one of the leading causes of
|
|
- Rosamond Payne
- 6 years ago
- Views:
Transcription
1 Long-Term Survival After Repeated Resection of Pulmonary Metastases From Colorectal Cancer Stefan Welter, MD, Jan Jacobs, MD, Thomas Krbek, MD, Bettina Krebs, MD, and Georgios Stamatis, MD Department of Thoracic Surgery, Ruhrlandklinik, Essen, Germany Background. The purpose of this study was to evaluate the outcome of patients undergoing repeated resection of pulmonary metastases from colorectal cancer and specify factors promising long-term survival. Methods. From January 1993 to December 2003, 175 patients were diagnosed and resected for pulmonary metastases of colorectal cancer. Follow-up information was collected for 169 patients, and 33 (19.5%) had had recurrent metastasectomies up to three times. Their follow-up information was updated in August The first repeated resection was performed for up to six bilateral metastases, the second and third metastasectomies were each unilateral and for a single metastasis only. Lymph node involvement was present in 5 patients who underwent repeat resections. Results. The overall (n 169) median survival was 47.2 months after the first metastasectomy. The 33 patients with repeated resections had a median survival of 72.6 months, with survival of 53.8% at 5 years and 20.6% at 10 years. After reoperation, age, sex, primary tumor stage, preoperative carcinoembryonic antigen, disease-free interval, prior resection of liver metastases, and lymph node involvement were not found to be of prognostic importance. The only factor that significantly influenced survival was the number of metastases (hazard risk, 1.299). Perioperative mortality even for repeated resections was 0%. Conclusions. Repeated resection of pulmonary metastases secondary to colorectal cancer is safe and can provide long-term survival for highly selected patients. (Ann Thorac Surg 2007;84:203 10) 2007 by The Society of Thoracic Surgeons Colon cancer is still one of the leading causes of cancer death in Western countries. After the initial diagnosis, more than two thirds of these patients undergo primary curative resection. Nonetheless, more than half of the resected patients eventually die from the underlying disease [1]. Tumor recurrence is usually due to distant metastases [2]. Patients with untreated metastatic disease have a 5-year survival of less than 5% [3]. But despite stage IV disease, some highly selected patients with only a few pulmonary metastases can undergo surgical metastasectomy and still have a curative option with a 5-year survival rate up to 60%. The results of 5206 cases assessed in the International Registry of Lung Metastases showed that lung metastasectomy in general is a safe and potentially curative procedure [4]. To date, very limited, but encouraging information about repeated pulmonary metastasectomy is available [5 9]. Depending on tumor size and location, number of metastases and performance status, repeated surgical resection can be offered, and even long-term survival is possible. In this retrospective study we reviewed our experience with recurrent pulmonary metastases from colorectal cancer and focused on the prognostic impact of repeated surgical interventions. Accepted for publication March 12, Address correspondence to Dr Welter, Department of Thoracic Surgery, Ruhrlandklinik, Tüschener Weg 40, Essen, 45239, Germany; stefan.we@t-online.de. Material and Methods Our hospital Ethics Committee approved this study and waived the need for individual consent. From January 1993 to December 2003, 175 patients with colorectal lung metastases were resected in our hospital, and 169 patients were available for further examination (Table 1). Six were lost to follow-up after discharge and were excluded from this study; none had a recurrent procedure. As of August 2006, 33 (19.5%) of the 169 former identified patients had at least one repeated thoracotomy for removal of recurrent metastases. Data Collection Preoperative, operative, and pathologic data were collected by review of medical records. Sequential operations on both lungs were counted as one resection with the date of first resection, and the number of metastases from each side was added. Follow-up information included date of death, tumor recurrence, and location and was gathered by written inquiries to the general practitioner, the oncologists, or (if otherwise impossible) the registry offices. The 33 patients with repeated operative procedures were followed up until August Three were still alive in June 2004, but could not be contacted in August Twenty-four patients died: 2 from comorbid disease, and the remaining 22 died from tumor recurrence. All had some sort of palliative chemotherapy before they died, but no patient had adjuvant chemotherapy or radiation directly after 2007 by The Society of Thoracic Surgeons /07/$32.00 Published by Elsevier Inc doi: /j.athoracsur
2 204 WELTER ET AL Ann Thorac Surg REPEATED RESECTION OF METASTASES 2007;84: Table 1. Patient Characteristics (n 169) Characteristic Patients, n (%) Age, mean (range) 63.5 ( ) Sex Male 96 (56.8) Female 73 (43.2) Primary tumor site Colon 73 (43.2) Rectum 96 (56.8) Prior resection of liver metastases Yes 37 (21.9) Number of metastases 1 81 (48) (36.1) 5 27 (15.9) Maximum tumor size 5 cm 150 (88.8) 5 cm 19 (11.2) Tumor recurrence Pulmonary only 39 (23.1) None 38 (22.5) Pulmonary others 34 (20.1) Others 50 (29.6) Unknown 8 (4.7) Major complications (268 operations) 41 (15.3) Arrhythmias 8 Pneumonia 9 Pulmonary embolism 1 Prolonged ventilation 2 Bronchopleural fistula 1 Empyema 4 Gastric ulcer bleeding 2 Others 14 the removal of pulmonary metastases. Nine patients were alive, and 6 (18.2%) were free of tumor. Staging The preoperative staging in our hospital consisted of abdominal ultrasound, computed tomography (CT) scan of the thorax and upper abdomen, fiberoptic bronchoscopy, and clinical examination. Brain and bone scans were only done if metastases were clinically suspected. Regular brain and bone scans were completed before repeated surgical interventions. Barium enema or colonoscopy to rule out local recurrence was accepted if not older than 6 months. As far as possible, wedge resection or segmentectomy was the procedure of choice; when necessary, pneumonectomy or completion pneumonectomy was performed. Lymph nodes suggestive of disease were sampled. After the first resection of metastases, the routine follow-up consisted of a chest roentgenogram, an ultrasound scan of the abdomen, and blood tests done by the oncologist every 3 months for 2 years and every 6 months thereafter. A yearly CT scan of the chest was advised. Definitions Initial TNM stage was extracted from external medical reports. All histologic reports of pulmonary metastases were reviewed and confirmed adenocarcinoma (G2) of intestinal origin. Preoperative selection criteria were completely resectable lesions in the lung, not more than 10 seen on CT scan, no evidence of metastases other than in the lung, resected primary colorectal tumor, no suspicion of mediastinal lymph node metastases, good performance score (World Health Organization, 0 to 2), sufficient lung function, and no contraindication due to concomitant disease. Patients with excessive pleural scarring or more than five metastases on one side were not accepted for repeated resection. If new nodules had evolved a minimum of 6 months after the last procedure, than reoperation was defined as repeated operation. An exception was a patient included from 1993 who had bilateral metastasectomy and one new metastasis only 2 months later, which was resected immediately. The pathologist s statement about microscopic resection margins were extracted for patients who had repeated operations, and the number of local recurrences was counted. The maximum resection (wedge, segment, lobe, lung) in one operation was counted as a type of resection, even if further wedge or segmental resections were performed. In case of multiple metastases in 1 patient, only the largest diameter was counted. Locoregional recurrence was defined as recurrent tumor in the same lobe. Table 2. Characteristics of 33 Patients Undergoing Repeated Resections Characteristic Patient, n (%) Age, mean (range) 62.3 ( ) Sex Male 20 (60.6) Female 13 (39.4) Primary tumor site Colon 15 (45.5) Rectum 18 (54.5) Primary tumor stage a I 4 (12.9) II 7 (22.5) III 10 (32.3) IV 10 (32.3) DFI, median months (range) DFI ( ) DFI ( ) DFI ( ) Prior resection of liver metastases Yes 11 No 22 a Data for 31 patients, 2 were unknown. DFI disease-free interval.
3 Ann Thorac Surg WELTER ET AL 2007;84: REPEATED RESECTION OF METASTASES 205 Operative Results Of the 33 patients with repeated surgical treatment, 20 were men (60.6%) and 13 were women (39.4%), with a median age of 63.8 years (range, 39.5 to 79.6) years. The initial tumor site was the colon in 15 (45.5%) and the rectum in 18 (54.5%). The initial tumor stage was stage I in 4 patients, II in 7, III in 10, and IV in 10, and 2 were unknown, according to International Union Against Cancer Classification (1997). The median disease-free interval (DFI) in the 33 patients from colorectal resection to pulmonary metastasectomy (DFI 1) was 27.0 months (range, 0 to 106 months). The median DFI from first to first repeated (DFI 2) and from first repeated to second repeated (DFI 3) metastasectomy was 16.8 months (range, 2.0 to 38.2 months) and 15.2 months (range, 6.9 to 20.8 months). Of the 33 patients, 11 (33.3%) had a complete resection of liver metastases before repeated pulmonary metastasectomy (Table 2). All together, 155 metastases had been removed with up to seven in a sequential bilateral thoracotomy. At the time of first lung resection, 15 patients had a single metastasis and 18 had multiple. At the time of first repeated lung resection, 15 patients had a single metastasis, and 18 had multiple (2 to 6). Six patients with a second and 1 patient with a third repeated metastasectomy had one lesion each. Locoregional recurrence was found in 22 of 33 patients during first repeated resection, 4 of 7 during second, and 1 of 1 during the third repeated resection. Table 3. Treatment and Pathologic Results of 33 Patients With Repeated Interventions Repeated Metastasectomy Fig 1. Kaplan-Meier probability of survival of 33 patients after the first metastasectomy. Median survival time was 72.6 months, and the survival rate was 53.8% at 5 years and 20.6% at 10 years. The pathologist described microscopically tumorfree resection margins concerning all specimens in 22 of 33 patients after the first metastasectomy, in 29 of 33 after the first repeated metastasectomy, in 4 of 7 after the second, and 1 out of 1 after the third repeated metastasectomy. During the first repeated resection, eight local recurrences were found where microscopically incomplete resection was found before. No patient who had microscopically incomplete resection Variable First Second Third (n 7) Fourth (n 1) Main resection a Wedge Segment Lobe Pneumonectomy 1 1 Total Number of metastases Maximum tumor size 5 cm cm 2 1 Lymph node involvement Pulmonary/hilar Mediastinal 1 Resection margins R0 (all sites) R1 ( 1 site) Locoregional recurrence Recurrence R1 site 8 0 a The main procedure of bilateral resections were counted separately. Fig 2. Kaplan-Meier probability of survival in 33 patients after the first repeated metastasectomy. Median survival time was 49.0 months, and the survival rate was 37.1% at 5 years and 13.8% at 10 years.
4 206 WELTER ET AL Ann Thorac Surg REPEATED RESECTION OF METASTASES 2007;84: Fig 3. Kaplan-Meier probability of survival in 7 patients after the second repeated metastasectomy. Median survival time was 54.6 months. after the second repeated metastasectomy was operated on a third time. The largest diameter of the first resected metastases was 0.7 to 8.0 cm according to the pathologist s measurement and was 0.7 to 5.5 cm in the repeated resections. At the first procedures, 50 unilateral and bilateral operations were performed in 33 patients, consisting of 29 wedge resections, 13 segmentectomies, and eight lobar resections as the main procedure. The next 37 first repeated operations consisted of 14 wedge, seven segmental, 15 lobar resections, and one pneumonectomy, including four bilateral interventions. These were again followed by seven second repeated resections on one side consisting of five wedge resections, one segmental, and one lobar resection, and again were followed by one completion pneumonectomy as the third repeated metastasectomy (Table 3). The surgical access was a muscle-saving anterioraxillary thoracotomy that allowed palpation of the whole lung in all patients, even those undergoing repeated operations. Two patients had incomplete removal of lung metastases after the first repeated procedure, and one after the second repeated thoracotomy; the latter had intrapulmonary lymph node involvement as well. Operative mortality included patients who died within 30 days after thoracotomy or during the same hospital stay and was 0%. The rate of major complications for all repeated operative treatments in the 33 patients was 22.0% (9/41). The latter included 4 patients with prolonged air leak, and 1 patient each with relevant arrhythmias, pneumonia, empyema, recurrent nerve palsy, and others. Lymph nodes suggestive for disease were sampled. Interlobar, hilar, or mediastinal lymph nodes were removed in 23 of 33 primary lung interventions and in 25 of 33, two of seven, and one of one first, second, and third repeated metastasectomies. The pathologist described up to 10 lymph nodes in 1 patient in the first, and up to 10, eight, and four lymph nodes in the first, second, and third repeated resection specimen. Lymph node metastases were found in 3 of 33 patients during the first intervention, and in 5 of 33 during one of the recurrent thoracotomies. Statistical Analysis The data were analyzed using the program SPSS 11.5 (SPSS Inc, Chicago, IL) for Windows (Microsoft, Redmond, WA). Probability of survival was calculated according to the method of Kaplan-Meier [10] using the date of the first pulmonary resection and the date of last follow-up or death of the patient as start and end points. The prognostic influence of variables on survival was analyzed using the log-rank test [11]. Cox proportional hazards model [12] was used to perform a multivariate analysis of prognostic factors. Variables with a value of p 0.15 were included into the stepwise regression model. A p 0.05 was considered significant. Stepwise regressions of parameters due to highest value of p were achieved with the likelihood quotient method (LR method). Results All pulmonary resections were performed in the Department of Thoracic Surgery at Ruhrlandklinik Essen. The initial colonic resections were all done in other hospitals. Fig 4. Kaplan-Meier probability of survival in 33 patients after the first metastasectomy, depending on the number of metastases. The survival difference between patients with 1 (thick black line), 2 to 4 (grey line) and 5 to 10 (thin black line) metastases, removed at the first metastasectomy, was statistically significant (p and p ).
5 Ann Thorac Surg WELTER ET AL 2007;84: REPEATED RESECTION OF METASTASES 207 Table 4. Univariate Analysis of Prognostic Factors (Log-Rank Test) First Metastasectomy First Repeated Metastasectomy Variable MST 95% CI Log-Rank p Value MST 95% CI Log-Rank p Value Age Sex M F PTS I II III IV DFI a NOM b b LM No Yes LNI No Yes a DFI 24 was not calculated for repeated resections. b Significant at p CI confidence interval; DFI disease-free interval; LM liver metastases; LNI lymph node involvement; MST median survival time; NOM number of metastases; PTS primary tumor stage. Survival The actuarial overall median survival (n 169) was 47.2 months (95% confidence interval, 39.8 to 54.5 months). Overall survival was 39.1% at 5 years and 20.0% at 10. After the first pulmonary metastasectomy, only 38 patients were free of tumor in June 2004, and 8 patients were unknown. A total of 123 (75.7%) patients faced tumor recurrence, of which 39 had intrapulmonary recurrence only. Six of them proved to be inoperable, and 33 had recurrent operations. Patients With Repeated Resections The median survival of the 33 patients who had repeated resections was 72.6 months, with a corresponding overall survival rate of 53.8% after 5 years and 20.6% after 10. The median survival after first and second repeated metastasectomy was 49.0 and 54.6 months, respectively (Figs 1, 2, and 3). The 2 patients with completion pneumonectomy survived 30 and 74 months but both died of tumor recurrence in the remaining lung. No significant age or sex related mortality was found. Only 17 of 33 patients had a carcinoembryonic antigen investigation before resection, and 5 were elevated with no significant impact on prognosis (p 0.49). Diseasefree interval from colon resection to first, second, and third metastasectomy, primary tumor stage, and lymph node involvement was not found to be of prognostic significance in the univariate analysis as well. The 5-year and 10-year survival of 11 patients with liver metastases was 42.4% and 21.2% compared with 59.1% and 21.5% for those without liver involvement; the difference was not significant (p 0.62). The number of metastases was the only strong predictor of survival in the univariate analysis (Fig 4). The survival difference between patients with a single and two to four metastases was significant (p 0.025) after the first metastasectomy and not significant (p 0.10) after the first repeated resection (Table 4). The 5-year survival of patients with one metastasis at the primary intervention was 79.0% compared with 33.3% for those with more than one lesion. No patient with more than one lesion at the initial pulmonary operation survived 10 years, despite repeated resections. A multivariate analysis of independent prognostic factors was done after the first and the first repeated metastasectomy using the Cox regression method. Covariables without significant values were stepwise excluded. Beginning with age, sex, primary tumor stage,
6 208 WELTER ET AL Ann Thorac Surg REPEATED RESECTION OF METASTASES 2007;84: Table 5. Multivariate Analysis of Prognostic Factors Covariable Estimator (B) Exp (B) (95% CI) disease free interval, number of metastases, size of metastases, preoperative liver metastases, and lymph node involvement, six iteration steps left three independent variables as statistically significant prognostic factors: disease free interval (hazard risk, 0.981), number of metastases (hazard risk, 1.299) and age (hazard risk, 0.933; Table 5). The same iteration procedure was performed after the first repeated removal of metastases, which identified the number of metastases (hazard risk, 1.276) as the only independent prognostic factor (Table 5). These multivariate results indicate that assuming that all other covariables are constant, the prolongation of the DFI by 1 month reduces the hazard by 1.9%, which means 20.6% per year. The patient with one more metastasis (n 1) has a (29.9%) increased risk to die. And every additional year of life before metastasectomy reduces the risk to die by 6.7%. Comment p Value First pulmonary metastasectomy DFI ( ) NOM ( ) Age ( ) First repeated pulmonary metastasectomy NOM ( ) CI confidence interval; DFI disease-free interval; NOM number of metastases. This investigation was especially focused on the question of whether repeated removal of lung metastases from colorectal cancer has a beneficial effect on survival. To date, resection of pulmonary metastases from colorectal cancer becomes an increasingly accepted method in the treatment of this cancer. Very limited but encouraging information is available about repeated surgical interventions for recurrent metastases from various primaries, yielding 5-year survival rates from 30.6% to 57% [5 9, 13, 14] and 53.8% in our study. Survival curves were found to be equal between first and first repeated metastasectomy for osteosarcomas [8], soft-tissue sarcoma [14], colorectal cancer [9, 15], and various tumor types [6, 7] in other series. We treated 33 patients for recurrent colorectal lung metastases with a repeated resection and found a 53.8% 5-year survival rate, which is almost equal to the results (52.1%) of Saito and colleagues [15]. Selection Criteria Because regular cancer follow-up is in the hands of oncologists, pneumologists, and general practitioners, only a highly selected group of repeated resection candidates were seen. A real weakness in this series is the lack of a formalized follow-up. We do not know how many patients might have been resectable a second or even third time if a thoracic surgeon had seen them routinely. From 169 patients, 33 (19.5%) had repeated procedures. This is even more than the 15% from the International Registry data [4] and the 14.6% described by Jaklitsch and colleagues [7], where a prospective follow-up after primary metastasectomy was established in the same department. Accepted inclusion criteria are the surgical and functional resectability and the exclusion of other distant organ metastases. The number of expected metastases did not influence the decision to perform a repeated metastasectomy in the reports of Kandioler and colleagues [6] and Jaklitsch and colleagues [7]. We did not perform a second or third repeated metastasectomy in case of more than one single lesion. Taking into account the results of this study that median survival after the second repeated metastasectomy was 54 months, this restriction does not seem to be necessary. Eleven initial microscopically incomplete resections caused eight local recurrences in the same lobe, whereas 14 were local recurrences after initially clear margins. Only three R1 resections did not lead to a local recurrence. This fact underlines the necessity for wide resection margins. Age should not be a selection criterion: operative mortality is low regardless of age, 0% in our series and up to 3% [5]. Repeated resections had a slightly elevated rate of major complications (22.0%) compared with the rate (15.3%) of first metastasectomy in 169 patients. Operative Access From the beginning, our policy was to perform open procedures, thus allowing the palpation of the whole lung for every metastasectomy. Other authors [4, 16 18] reported that up to 30% of metastases are missed on CT scan, and the success rate to detect all nodules by video assisted thoracoscopic surgery was only 22% [18]. Others even performed repeated resections with video assistance [7, 13] and could show excellent survival rates. Prognostic Factors AGE. In the 33 patients who had repeated resections, we found a survival advantage for the elderly in the multivariate analysis. We have not found an explanation for this in the literature on pulmonary metastasectomy and we cannot provide an explanation from our data. A similar age-related survival difference in stage I non-small cell lung cancer was found by Cerfolio and Bryant [19], who compared elderly patients with a younger control group. The explanation was given in the greater percentage of less aggressive, well-differentiated tumors in the older age group and the detection of earlier tumor stages. DISEASE-FREE INTERVAL. The DFI is a prognostic factor of low importance in our study. In the group with repeated resections, we found the DFI ( 24 months) from colorec-
7 Ann Thorac Surg WELTER ET AL 2007;84: REPEATED RESECTION OF METASTASES 209 tal resection to first metastasectomy (DFI 1) to be significantly (p 0.032) correlated with a better prognosis, associated with a hazard risk of for every additional month without tumor recurrence. There is little doubt in other series that synchronous metastases have a minor prognosis and a long DFI from primary tumor resection to first metastasectomy is superior [4, 8, 13, 14, 20]. The International Registry [4] showed the best prognostic group being those with a single resectable metastasis and a DFI of more than 3 years with no other risk factor. Furthermore, resectability is most important. As Jaklitsch and colleagues [7] could show, prognosis is good (5-year survival, 33% to 59%) as long as repeated resections can provide local control. Once local control had been lost, further survival fell dramatically to a median of 8 months, regardless of the number of previous procedures. LIVER METASTASES. In our series, as well as in others [15, 20, 21, 22], resected liver metastases were not associated with a decreased survival. Patients in our series with repeated resections and removed liver metastases had a 5-year survival of 42.4% compared with 59.1% of those without liver involvement (p 0.624). NUMBER OF METASTASES. The number of metastases is the most important predictor of survival [5, 14, 20, 22 24]. The results of 5206 cases of the International Registry [4], including various histologies, showed a survival of 43% at 5 years for single metastasis and 27% for more than four metastases. Even in repeated resections, the number of metastases is most important. We found a median survival of 95.3, 51.4, and 33.7 months in the groups with one, two to four, and more than 4 metastases. The difference was statistically significant (p and p 0.009). LYMPH NODE INVOLVEMENT. We did not find a prognostic influence of lymph node metastases in the 33 patients with repeated pulmonary resections. The number of cases is probably too small to make further statements. Lymph node involvement was not investigated in the other series with repeated carcinoma resections [6, 7, 13]. Completion pneumonectomy (CP) for recurrent pulmonary metastases is still controversial. We performed two CPs. Survival was 74 months and 30 months after CP, and both patients died of tumor recurrence. Much worse results for CP were found by Grunenwald and colleagues [25] in a 1997 series with a median survival of 6 months in of 12 patients with pulmonary metastases and by Jungraithmayr and colleagues [26] in a series with a 3-year survival rate of 34% in 9 patients. Both authors did not see a survival benefit for CP. Better results were found by Koong and colleagues [27] in 1999, in which 38 patients had a CP with an operative mortality of 3% and a 5-year survival of 30%. CHEMOTHERAPY. Finally, chemotherapy has to be discussed. A comparison is very difficult because we have not found a trial that differentiates resectable from irresectable lung involvement before chemotherapy, and nearly all series contain different sites of metastases, not only restricted to the lung [28 30]. Even the best prognostic groups (one tumor site, good performance status) had a median survival of only 15 to 19 months [28, 31, 32]. The addition of bevacizumab to fluorouracil and irinotecan (in a randomized controlled study with 923 patients) can prolong median survival up to 20 months in metastatic disease [30]. The objective response rate was 44.8% including only 3.7% complete responses, 2.8% of patients died from toxicity, and about 50% of patients had further second-line and third-line chemotherapy. In this context, the operative results appear to be excellent, but a direct comparison is not possible. All surgical candidates were highly selected and had some form of chemotherapy in the course of their disease. Conclusion Repeated resection of pulmonary metastases in colorectal cancer is indicated in some highly selected patients. If other organ involvement can be ruled out, repeated thoracotomy can be offered with a low mortality and slightly elevated morbidity. In the patient with one or few recurrent operable metastases, chemotherapy does not offer better results. Some patients can be cured, and long-term survival is possible. References 1. Rosen M, Chan L, Beart RW, Vukasin P, Anthone G. Follow-up of colorectal cancer: a meta-analysis. Dis Colon Rectum 1998;41: Hermanek P, Wiebelt H, Riedel S, Staimmer D, Hermanek P. Long term results of surgical therapy of colon cancer. Results of the Colorectal Cancer Study Group. Chirurg 1994;65: Poon MA, O Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7: Pastorino U, Buyse M, Friedel G, et al. Long-term results of lung metastasectomy: prognostic analysis based on 5206 cases. J Thorac Cardiovasc Surg 1997;113: McAfee MK, Allen MS, Trastek VF, Ilstrup DM, Deschamps C, Pairolero PC. Colorectal lung metastases: results of surgical excision. Ann Thorac Surg 1992;53: Kandioler D, Krömer E, Tüchler H, et al. Long-term results after repeated surgical removal of pulmonary metastases. Ann Thorac Surg 1998;65: Jaklitsch MT, Mery CM, Lukanich JM, et al. Sequential thoracic metastasectomy prolongs survival by reestablishing local control within the chest. J Thorac Cardiovasc Surg 2001;121: Briccoli A, Rocca M, Salone M, et al. Resection of recurrent pulmonary metastases in patients with osteosarcoma. Cancer 2005;104: Ogata Y, Matono K, Hayashi A, et al. Repeat pulmonary resection for isolated recurrent lung metastases yields results comparable to those after first pulmonary resection in colorectal cancer. World J Surg 2005;29: Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Soc 1958;53: Peto R, Peto J. Asymptotically efficient rank and invariant procedures. J R Stat Soc 1972;135: Cox DR. Regression models and life-tables. J R Stat Soc (Ser B Stat Methodol) 1972;34: Groeger AM, Kandioler D, Mueller MR, End A, Eckersberger F, Wolner E. Survival after surgical treatment of recurrent pulmonary metastases. Eur J Cardiothorac Surg 1997;12: Weiser MR, Downey RJ, Leung DH, Brennan MF. Repeat resection of pulmonary metastases in patients with softtissue sarcoma. J Am Coll Surg 2000;191:
8 210 WELTER ET AL Ann Thorac Surg REPEATED RESECTION OF METASTASES 2007;84: Saito Y, Omiya H, Kohno K, et al. Pulmonary metastasectomy for 165 patients with colorectal carcinoma: a prognostic assessment. J Thorac Cardiovasc Surg 2002;124: Loehe F, Kobinger S, Hatz RA, Helmberger T, Loehrs U, Fuerst H. Value of systematic mediastinal lymph node dissection during pulmonary metastasectomy. Ann Thorac Surg 2001;72: McCormack PM, Ginsberg KB, Bains MS, et al. Accuracy of lung imaging in metastases with implications for the role of thoracoscopy. Ann Thorc Surg 1993;56: McCormack PM, Bains MS, Begg CB, et al. Role of videoassisted thoracic surgery in the treatment of pulmonary metastases: results of a prospective trial. Ann Thorac Surg 1996;62: Cerfolio RJ, Bryant AS. Survival and outcomes of pulmonary resection for non-small cell lung cancer in the elderly: a nested case-control study. Ann Thorac Surg 2006;82: Kobayashi K, Kawamura M, Ishihara T. Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer. J Thorac Cardiovasc Surg 1999;118: Ike H, Shimada H, Togo S, Yamaguchi S, Ichikawa Y, Tanaka K. Sequential resection of lung metastasis following partial hepatectomy for colorectal cancer. Br J Surg 2002;89: Regnard JF, Grunenwald D, Spaggiari L, et al. Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 1998;66: Okumura S, Kondo H, Tsuboi M, et al. Pulmonary resection for metastatic colorectal cancer: experiences with 159 patients. J Thorac Cardiovasc Surg 1996;112: Pfannschmidt J, Muley T, Hoffmann H, Dienemann H. Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: experiences in 167 patients. J Thorac Cardiovasc Surg 2003;126: Grunenwald D, Spaggiari L, Girard P, Baldeyrou P, Filaire M, Dennewald G. Completion pneumonectomy for lung metastases: is it justified? Eur J Cardiothorac Surg 1997;12: Jungraithmayr W, Hasse J, Stoelben E. Completion pneumonectomy for lung metastases. Eur J Surg Oncol 2004;30: Koong HN, Pastorino U, Ginsberg RJ. Is there a role for pneumonectomy in pulmonary metastases? Ann Thorac Surg 1999;68: Kohne CH, Cunningham D, Di CF, et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002;13: Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343: Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350: De Gramont A, Figer A, Seymour M, et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 2000;18: Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of Oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000;18:
Pulmonary Resection for Metastases from Colorectal Cancer
ORIGINAL ARTICLE Pulmonary Resection for Metastases from Colorectal Cancer Paul M. van Schaik, MD,* Ewout A. Kouwenhoven, MD, PhD,* Robert J. Bolhuis, MD,* Bonne Biesma, MD, PhD, and Koop Bosscha, MD,
More informationPulmonary resection for metastatic colorectal carcinoma was first performed
General Thoracic Surgery Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment Yukihito Saito, MD, a Hideyasu Omiya, MD, a Keijiro Kohno, MD, b Takanobu Kobayashi,
More informationMore than half of the patients undergoing resection for colorectal
General Thoracic Surgery Pfannschmidt et al Prognostic factors and survival after complete resection of pulmonary metastases from colorectal carcinoma: Experiences in 167 patients Joachim Pfannschmidt,
More informationValue of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy
Value of Systematic Mediastinal Lymph Node Dissection During Pulmonary Metastasectomy Florian Loehe, MD, Sonja Kobinger, MD, Rudolf A. Hatz, MD, Thomas Helmberger, MD, Udo Loehrs, MD, and Heinrich Fuerst,
More informationHistopathologic Prognostic Factors in Resected Colorectal Lung Metastases
Histopathologic Prognostic Factors in Resected Colorectal Lung Metastases Satoshi Shiono, MD, Genichiro Ishii, MD, Kanji Nagai, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, Yukinori Murata, MT, Koji Tsuta,
More informationSurgical resection of pulmonary metastases is an established
Long-Term Results After Pulmonary Resection of Renal Cell Carcinoma Metastases Stefan Piltz, MD, Georgios Meimarakis, MD, Matthias W. Wichmann, MD, Rudolf Hatz, MD, Friedrich Wilhelm Schildberg, MD, and
More informationAfter primary tumor treatment, 30% of patients with malignant
ESTS METASTASECTOMY SUPPLEMENT Alberto Oliaro, MD, Pier L. Filosso, MD, Maria C. Bruna, MD, Claudio Mossetti, MD, and Enrico Ruffini, MD Abstract: After primary tumor treatment, 30% of patients with malignant
More informationMore than half the patients who undergo resection
Early Intrapulmonary Recurrence After Pulmonary Metastasectomy Related to Colorectal Cancer Mi Ri Hwang, MD, Ji Won Park, MD, Dae Yong Kim, MD, Hee Jin Chang, MD, Sun Young Kim, MD, Hyo Seong Choi, MD,
More informationSurgical Management of Advanced Stage Colon Cancer. Nathan Huber, MD 6/11/14
Surgical Management of Advanced Stage Colon Cancer Nathan Huber, MD 6/11/14 Colon Cancer Overview Approximately 50,000 attributable deaths per year Colorectal cancer is the 3 rd most common cause of cancer-related
More informationPulmonary metastases of breast cancer. When is resection indicated?
European Journal of Cardio-thoracic Surgery 34 (2008) 1228 1234 www.elsevier.com/locate/ejcts Pulmonary metastases of breast cancer. When is resection indicated? Stefan Welter a, *, Jan Jacobs a, Thomas
More informationAlthough the international TNM classification system
Prognostic Significance of Perioperative Serum Carcinoembryonic Antigen in Non-Small Cell Lung Cancer: Analysis of 1,000 Consecutive Resections for Clinical Stage I Disease Morihito Okada, MD, PhD, Wataru
More informationClinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication for Repeat Metastasectomy
Respiratory Medicine Volume 2015, Article ID 570314, 5 pages http://dx.doi.org/10.1155/2015/570314 Clinical Study Metastasectomy of Pulmonary Metastases from Osteosarcoma: Prognostic Factors and Indication
More informationSurgical Approaches to Pulmonary Metastases
Surgical Approaches to Pulmonary Metastases Raja M Flores MD Professor and Chief Thoracic Surgery Mount Sinai School of Medicine New York, New York History of Lung Metastasectomy 1882 Weinlechner +CW 1926
More informationSuperior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis
ORIGINAL ARTICLES: Superior and Basal Segment Lung Cancers in the Lower Lobe Have Different Lymph Node Metastatic Pathways and Prognosis Shun-ichi Watanabe, MD, Kenji Suzuki, MD, and Hisao Asamura, MD
More informationThe prognostic importance of the number of metastases in pulmonary metastasectomy of colorectal cancer
Cho et al. World Journal of Surgical Oncology (2015) 13:222 DOI 10.1186/s12957-015-0621-7 WORLD JOURNAL OF SURGICAL ONCOLOGY RESEARCH Open Access The prognostic importance of the number of metastases in
More informationPrognostic value of visceral pleura invasion in non-small cell lung cancer q
European Journal of Cardio-thoracic Surgery 23 (2003) 865 869 www.elsevier.com/locate/ejcts Prognostic value of visceral pleura invasion in non-small cell lung cancer q Jeong-Han Kang, Kil Dong Kim, Kyung
More informationThe lungs are the second most frequent site for metastases
Prognostic Factors for Survival After Pulmonary Resection of Metastatic Renal Cell Carcinoma Joachim Pfannschmidt, MD, Hans Hoffmann, MD, PhD, Thomas Muley, PhD, Sabine Krysa, MD, Christine Trainer, MD,
More informationORIGINAL RESEARCH. International Journal of Surgery
International Journal of Surgery 11 (2013) 244e248 Contents lists available at SciVerse ScienceDirect International Journal of Surgery journal homepage: www.theijs.com Original research Pulmonary metastasectomy
More informationSurgical Management of Pulmonary Metastases. Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital
Surgical Management of Pulmonary Metastases Dr AG Jacobs Principal Specialist Dept Cardiothoracic Surgery Steve Biko Academic Hospital Introduction Lungs 2 nd most common site of metastatic deposition
More informationPulmonary Metastasectomy for Pulmonary Metastases of Head and Neck Squamous Cell Carcinomas
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationThe right middle lobe is the smallest lobe in the lung, and
ORIGINAL ARTICLE The Impact of Superior Mediastinal Lymph Node Metastases on Prognosis in Non-small Cell Lung Cancer Located in the Right Middle Lobe Yukinori Sakao, MD, PhD,* Sakae Okumura, MD,* Mun Mingyon,
More informationThe roles of adjuvant chemotherapy and thoracic irradiation
Factors Predicting Patterns of Recurrence After Resection of N1 Non-Small Cell Lung Carcinoma Timothy E. Sawyer, MD, James A. Bonner, MD, Perry M. Gould, MD, Robert L. Foote, MD, Claude Deschamps, MD,
More informationPULMONARY RESECTION FOR METASTATIC COLORECTAL CANCER: EXPERIENCES WITH 159 PATIENTS
PULMONARY RESECTION FOR METASTATIC COLORECTAL CANCER: EXPERIENCES WITH 159 PATIENTS Shinji Okumura, MD Haruhiko Kondo, MD Masahiro Tsuboi, MD Haruhiko Nakayama, MD Hisao Asamura, MD Ryosuke Tsuchiya, MD
More informationWhen a solitary pulmonary lesion (SPL) is found in
GENERAL THORACIC Resection of Solitary Pulmonary Lesion Is Beneficial to Patients With a History of Malignancy Miki Sakamoto, MD, Tomohiro Murakawa, MD, Kentaro Kitano, MD, Tomonori Murayama, MD, Takehiro
More informationLung cancer is a major cause of cancer deaths worldwide.
ORIGINAL ARTICLE Prognostic Factors in 3315 Completely Resected Cases of Clinical Stage I Non-small Cell Lung Cancer in Japan Teruaki Koike, MD,* Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, Yasunori Sohara,
More informationPrognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai, China
www.springerlink.com Chin J Cancer Res 23(4):265 270, 2011 265 Original Article Prognostic Factors for Survival of Stage IB Upper Lobe Non-small Cell Lung Cancer Patients: A Retrospective Study in Shanghai,
More informationSafety distance in the resection of colorectal lung metastases: A prospective evaluation of satellite tumor cells with immunohistochemistry
Safety distance in the resection of colorectal lung metastases: A prospective evaluation of satellite tumor cells with immunohistochemistry Stefan Welter, MD, a Dirk Theegarten, MD, b Tanja Trarbach, MD,
More informationStandard treatment for pulmonary metastasis of non-small
ORIGINAL ARTICLE Resection of Pulmonary Metastasis of Non-small Cell Lung Cancer Kenichi Okubo, MD,* Toru Bando, MD,* Ryo Miyahara, MD,* Hiroaki Sakai, MD,* Tsuyoshi Shoji, MD,* Makoto Sonobe, MD,* Takuji
More informationLYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG
LYMPH NODE METASTASIS IN SMALL PERIPHERAL ADENOCARCINOMA OF THE LUNG Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Takehiro Watanabe, MD a Yuzo Kurita, MD b Akira Yokoyama, MD b Keiichi
More informationIn 1989, Deslauriers et al. 1 described intrapulmonary metastasis
ORIGINAL ARTICLE Prognosis of Resected Non-Small Cell Lung Cancer Patients with Intrapulmonary Metastases Kanji Nagai, MD,* Yasunori Sohara, MD, Ryosuke Tsuchiya, MD, Tomoyuki Goya, MD, and Etsuo Miyaoka,
More informationPulmonary resection remains the most effective. Survival in Synchronous vs Single Lung Cancer. Upstaging Better Reflects Prognosis
Survival in Synchronous vs Single Lung Cancer Upstaging Better Reflects Prognosis Marcel Th. M. van Rens, MD; Pieter Zanen, MD, PhD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD;
More informationPulmonary metastasectomy in uterine malignancies: outcome and prognostic factors
Original Article Pulmonary metastasectomy in uterine malignancies: outcome and prognostic factors Marco Anile, Sara Mantovani, Ylenia Pecoraro, Carolina Carillo, Lorenzo Gherzi, Andreina Pagini, Erino
More informationCASE REPORT. Introduction. Case series reports. J Thorac Dis 2012;4(S1): DOI: /j.issn s003
CASE REPORT Lost in time pulmonary metastases of renal cell carcinoma: complete surgical resection of metachronous metastases, 18 and 15 years after nephrectomy Kosmas Tsakiridis 1, Aikaterini N Visouli
More informationsarcoma Reprint requests: Dr M H Robinson, YCRC Senior Lecturer Clinical Oncology, Weston Park Hospital, Whitham Road, Sheffield S10 2SJ.
1994, The British Journal of Radiology, 67, 129-135 Lung metastasectomy sarcoma in patients with soft tissue 1 M H ROBINSON, MD, MRCP, FRCR, 2 M SHEPPARD, FRCPATH, 3 E MOSKOVIC, MRCP, FRCR and 4 C FISHER,
More informationComplete surgical excision remains the greatest potential
ORIGINAL ARTICLE Wedge Resection for Non-small Cell Lung Cancer in Patients with Pulmonary Insufficiency: Prospective Ten-Year Survival John P. Griffin, MD,* Charles E. Eastridge, MD, Elizabeth A. Tolley,
More informationPhysician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer
Physician Follow-Up and Guideline Adherence in Post- Treatment Surveillance of Colorectal Cancer Gabriela M. Vargas, MD Kristin M. Sheffield, PhD, Abhishek Parmar, MD, Yimei Han, MS, Kimberly M. Brown,
More informationIn the past, pulmonary metastases (PM) were considered
Original Article The Role of Extended Pulmonary Metastasectomy Monica Casiraghi, MD,* Patrick Maisonneuve, Eng, Daniela Brambilla, Msc,* Francesco Petrella, MD,* Piergiorgio Solli, MD,* Juliana Guarize,
More informationProper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer
Proper Treatment Selection May Improve Survival in Patients With Clinical Early-Stage Nonsmall Cell Lung Cancer Özcan Birim, MD, A. Pieter Kappetein, MD, PhD, Tom Goorden, MD, Rob J. van Klaveren, MD,
More informationAlthough ipsilateral intrapulmonary metastasis (PM), Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis
Evaluation of TMN Classification for Lung Carcinoma With Ipsilateral Intrapulmonary Metastasis Morihito Okada, MD, Noriaki Tsubota, MD, Masahiro Yoshimura, MD, Yoshifumi Miyamoto, MD, and Reiko Nakai,
More informationPulmonary laser resections: Technical aspects and results in colorectal cancer
Pulmonary laser resections: Technical aspects and results in colorectal cancer Bernward Passlick Professor of Thoracic Surgery Dept. of Thoracic Surgery University of Freiburg Germany Pulmonary laser resections
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Ablative therapy, nonsurgical, for pulmonary metastases of soft tissue sarcoma, 279 280 Adipocytic tumors, atypical lipomatous tumor vs. well-differentiated
More informationORIGINAL PAPER. Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery
Nagoya J. Med. Sci. 79. 37 ~ 42, 2017 doi:10.18999/nagjms.79.1.37 ORIGINAL PAPER Marginal pulmonary function is associated with poor short- and long-term outcomes in lung cancer surgery Naoki Ozeki, Koji
More informationPrognostic Factors and Survival after Pulmonary Resection ofmetastaticrenalcellcarcinoma
European Urology European Urology 48 (2005) 77 82 Kidney Cancer Prognostic Factors and Survival after Pulmonary Resection ofmetastaticrenalcellcarcinoma Hans-Stefan Hofmann*, Heinz Neef, Katharina Krohe,
More informationIndeterminate Pulmonary Nodules in Patients with Colorectal Cancer
Indeterminate Pulmonary Nodules in Patients with Colorectal Cancer Jai Sule 1, Kah Wai Cheong 2, Stella Bee 2, Bettina Lieske 2,3 1 Dept of Cardiothoracic and Vascular Surgery, University Surgical Cluster,
More informationThe pathophysiology of pulmonary metastases is initiated
Surgical Management of Pulmonary Metastases Loretta Erhunmwunsee, MD, and Thomas A. D Amico, MD Department of Surgery, Duke University Medical Center, Durham, North Carolina Metastasectomy is the only
More informationCarcinoma of the Lung
THE ANNALS OF THORACIC SURGERY Journal of The Society of Thoracic Surgeons and the Southern Thoracic Surgical Association VOLUME 1 I - NUMBER 3 0 MARCH 1971 Carcinoma of the Lung M. L. Dillon, M.D., and
More informationTreatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard
Treatment of Clinical Stage I Lung Cancer: Thoracoscopic Lobectomy is the Standard AATS General Thoracic Surgery Symposium May 5, 2010 Thomas A. D Amico MD Professor of Surgery, Duke University Medical
More informationNumber of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival
Number of Metastatic Lymph Nodes in Resected Non Small Cell Lung Cancer Predicts Patient Survival Jin Gu Lee, MD, Chang Young Lee, MD, In Kyu Park, MD, Dae Joon Kim, MD, Seong Yong Park, MD, Kil Dong Kim,
More informationManagement of Lung Metastases from Colorectal Cancer: Video-Assisted Thoracoscopic Surgery versus Thoracotomy A Case-Matched Study
98 Original Thoracic Management of Lung Metastases from Colorectal Cancer: Video-Assisted Thoracoscopic Surgery versus Thoracotomy A Case-Matched Study Yin-Kai Chao 1 Hao-Cheng Chang 2 Yi-Cheng Wu 1 Yun-hen
More informationVideo-Mediastinoscopy Thoracoscopy (VATS)
Surgical techniques Video-Mediastinoscopy Thoracoscopy (VATS) Gunda Leschber Department of Thoracic Surgery ELK Berlin Chest Hospital, Berlin, Germany Teaching Hospital of Charité Universitätsmedizin Berlin
More informationLong-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules
Long-term Follow-up for Patients with Papillary Thyroid Carcinoma Treated as Benign Nodules YASUHIRO ITO, TAKUYA HIGASHIYAMA, YUUKI TAKAMURA, AKIHIRO MIYA, KAORU KOBAYASHI, FUMIO MATSUZUKA, KANJI KUMA
More informationWe are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists. International authors and editors
We are IntechOpen, the world s leading publisher of Open Access books Built by scientists, for scientists 3,800 116,000 120M Open access books available International authors and editors Downloads Our
More informationMarcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans R. J. Elbers, MD, PhD; and Jules M. M. van den Bosch, MD, PhD, FCCP
Prognostic Assessment of 2,361 Patients Who Underwent Pulmonary Resection for Non-small Cell Lung Cancer, Stage I, II, and IIIA* Marcel Th. M. van Rens, MD; Aart Brutel de la Rivière, MD, PhD, FCCP; Hans
More informationLymph node dissection for lung cancer is both an old
LOBE-SPECIFIC EXTENT OF SYSTEMATIC LYMPH NODE DISSECTION FOR NON SMALL CELL LUNG CARCINOMAS ACCORDING TO A RETROSPECTIVE STUDY OF METASTASIS AND PROGNOSIS Hisao Asamura, MD Haruhiko Nakayama, MD Haruhiko
More informationLung cancer pleural invasion was recognized as a poor prognostic
Visceral pleural invasion classification in non small cell lung cancer: A proposal on the basis of outcome assessment Kimihiro Shimizu, MD a Junji Yoshida, MD a Kanji Nagai, MD a Mitsuyo Nishimura, MD
More informationComplex Thoracoscopic Resections for Locally Advanced Lung Cancer
Complex Thoracoscopic Resections for Locally Advanced Lung Cancer Duke Thoracoscopic Lobectomy Workshop March 21, 2018 Thomas A. D Amico MD Gary Hock Professor of Surgery Section Chief, Thoracic Surgery,
More informationBronchogenic Carcinoma
A 55-year-old construction worker has smoked 2 packs of ciggarettes daily for the past 25 years. He notes swelling in his upper extremity & face, along with dilated veins in this region. What is the most
More informationBACKGROUND: STUDY DESIGN: RESULTS: CONCLUSIONS:
Improved Survival after Resection of Liver and Lung Colorectal Metastases Compared with Liver-Only Metastases: A Study of 112 Patients with Limited Lung Metastatic Disease Antoine Brouquet, MD, Jean Nicolas
More informationVideo-assisted thoracic surgery (VATS) for resection of metastatic adenocarcinoma as an acceptable alternative
Surg Endosc (2009) 23:1947 1954 DOI 10.1007/s00464-008-0243-z Video-assisted thoracic surgery (VATS) for resection of metastatic adenocarcinoma as an acceptable alternative Marilee Carballo Æ Mary S. Maish
More informationTreatment of oligometastatic NSCLC
Treatment of oligometastatic NSCLC Jarosław Kużdżał Department of Thoracic Surgery Jagiellonian University Collegium Medicum, John Paul II Hospital, Cracow New idea? 14 NSCLC patients with solitary extrathoracic
More informationSurgical treatment in non-small cell lung cancer with pulmonary oligometastasis
He et al. World Journal of Surgical Oncology (2017) 15:36 DOI 10.1186/s12957-017-1105-8 RESEARCH Open Access Surgical treatment in non-small cell lung cancer with pulmonary oligometastasis Jinyuan He,
More informationT3 NSCLC: Chest Wall, Diaphragm, Mediastinum
for T3 NSCLC: Chest Wall, Diaphragm, Mediastinum AATS Postgraduate Course April 29, 2012 Thomas A. D Amico MD Professor of Surgery, Chief of Thoracic Surgery Duke University Health System Disclosure No
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/23566
More informationIS RESECTION OF PULMONARY AND HEPATIC METASTASES WARRANTED IN PATIENTS WITH COLORECTAL CANCER?
IS RESECTION OF PULMONARY AND HEPATIC METASTASES WARRANTED IN PATIENTS WITH COLORECTAL CANCER? Brigitta J. Robinson, MD a Thomas W. Rice, MD a Scott A. Strong, MD b Lisa A. Rybicki, MS c Eugene H. Blackstone,
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GASTROINTESTINAL RECTAL CANCER GI Site Group Rectal Cancer Authors: Dr. Jennifer Knox, Dr. Mairead McNamara 1. INTRODUCTION 3 2. SCREENING AND
More informationResected Synchronous Primary Malignant Lung Tumors: A Population-Based Study
ORIGINAL ARTICLES: SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://cme.ctsnetjournals.org. To take the CME activity related to this article, you must have either an STS
More informationPredictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer
Original Article Predictive risk factors for lymph node metastasis in patients with small size non-small cell lung cancer Feichao Bao, Ping Yuan, Xiaoshuai Yuan, Xiayi Lv, Zhitian Wang, Jian Hu Department
More informationPulmonary Resection for Metastatic Adrenocortical Carcinoma: The National Cancer Institute Experience
Pulmonary Resection for Metastatic Adrenocortical Carcinoma: The National Cancer Institute Experience Clinton D. Kemp, MD,* R. Taylor Ripley, MD,* Aarti Mathur, MD, Seth M. Steinberg, PhD, Dao M. Nguyen,
More informationThoracoscopic Lobectomy for Locally Advanced Lung Cancer. Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014
for Locally Advanced Lung Cancer Masters of Minimally Invasive Thoracic Surgery Orlando September 19, 2014 Thomas A. D Amico MD Gary Hock Endowed Professor and Vice Chair of Surgery Chief Thoracic Surgery
More informationCase Scenario 1. The patient agreed to a CT guided biopsy of the left upper lobe mass. This was performed and confirmed non-small cell carcinoma.
Case Scenario 1 An 89 year old male patient presented with a progressive cough for approximately six weeks for which he received approximately three rounds of antibiotic therapy without response. A chest
More informationCOLORECTAL CANCER CASES
COLORECTAL CANCER CASES Case #1 Case #2 Colorectal Cancer Case 1 A 52 year-old female attends her family physician for her yearly complete physical examination. Her past medical history is significant
More informationPeritoneal Involvement in Stage II Colon Cancer
Anatomic Pathology / PERITONEAL INVOLVEMENT IN STAGE II COLON CANCER Peritoneal Involvement in Stage II Colon Cancer A.M. Lennon, MB, MRCPI, H.E. Mulcahy, MD, MRCPI, J.M.P. Hyland, MCh, FRCS, FRCSI, C.
More informationThe metastatic behavior of renal cell carcinoma (RCC) Renal Cell Carcinoma Lung Metastases Surgery: Pathologic Findings and Prognostic Factors
Renal Cell Carcinoma Lung Metastases Surgery: Pathologic Findings and Prognostic Factors Jalal Assouad, MD, Boriana Petkova, MD, Pascal Berna, MD, Antoine Dujon, MD, Christophe Foucault, MD, and Marc Riquet,
More informationVisceral pleural involvement (VPI) of lung cancer has
Visceral Pleural Involvement in Nonsmall Cell Lung Cancer: Prognostic Significance Toshihiro Osaki, MD, PhD, Akira Nagashima, MD, PhD, Takashi Yoshimatsu, MD, PhD, Sosuke Yamada, MD, and Kosei Yasumoto,
More informationLymph node ratio as a prognostic factor in stage III colon cancer
Lymph node ratio as a prognostic factor in stage III colon cancer Emad Sadaka, Alaa Maria and Mohamed El-Shebiney. Clinical Oncology department, Faculty of Medicine, Tanta University, Egypt alaamaria1@hotmail.com
More informationSurgical resection is the first treatment of choice for
Predictors of Lymph Node and Intrapulmonary Metastasis in Clinical Stage IA Non Small Cell Lung Carcinoma Kenji Suzuki, MD, Kanji Nagai, MD, Junji Yoshida, MD, Mitsuyo Nishimura, MD, and Yutaka Nishiwaki,
More informationTreatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer
Treatment Strategy for Patients With Surgically Discovered N2 Stage IIIA Non-Small Cell Lung Cancer Ryoichi Nakanishi, MD, Toshihiro Osaki, MD, Kozo Nakanishi, MD, Ichiro Yoshino, MD, Takashi Yoshimatsu,
More informationSurgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study
Original article Annals of Gastroenterology (2013) 26, 346-352 Surgical resection improves survival in pancreatic cancer patients without vascular invasion- a population based study Subhankar Chakraborty
More informationMEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER
MEDIASTINAL LYMPH NODE METASTASIS IN PATIENTS WITH CLINICAL STAGE I PERIPHERAL NON-SMALL-CELL LUNG CANCER Tsuneyo Takizawa, MD a Masanori Terashima, MD a Teruaki Koike, MD a Hideki Akamatsu, MD a Yuzo
More informationORIGINAL ARTICLE. A Second Liver Resection Due to Recurrent Colorectal Liver Metastases. accepted as the only curative
ORIGINAL ARTICLE A Second Liver Resection Due to Recurrent Colorectal Liver Metastases Antonio Sa Cunha, MD; Christophe Laurent, MD; Alexandre Rault, MD; Philippe Couderc, MD; Eric Rullier, MD; Jean Saric,
More informationTreatment strategy of metastatic rectal cancer
35.Schweizerische Koloproktologie-Tagung Treatment strategy of metastatic rectal cancer Gilles Mentha University hospital of Geneva Bern, January 18th, 2014 Colorectal cancer is the third most frequent
More informationORIGINAL ARTICLE. Benefit of Surgical Treatment of Lung Metastasis in Soft Tissue Sarcoma
ORIGINAL ARTICLE Benefit of Surgical Treatment of Lung Metastasis in Soft Tissue Sarcoma Alexander Rehders, MD; Stefan B. Hosch, MD; Peter Scheunemann, MD; Nikolas H. Stoecklein, MD; Wolfram T. Knoefel,
More informationChirurgie beim oligo-metastatischen NSCLC
24. Ärzte-Fortbildungskurs in Klinischer Onkologie 20.-22. Februar 2014, Kantonsspital St. Gallen Chirurgie beim oligo-metastatischen NSCLC Prof. Dr. med. Walter Weder Klinikdirektor Thoraxchirurgie, UniversitätsSpital
More informationThe accurate assessment of lymph node involvement is
ORIGINAL ARTICLE Which is the Better Prognostic Factor for Resected Non-small Cell Lung Cancer The Number of Metastatic Lymph Nodes or the Currently Used Nodal Stage Classification? Shenhai Wei, MD, PhD,*
More informationVATS Metastasectomy. Inderpal (Netu) S. Sarkaria, MD, FACS
VATS Metastasectomy Inderpal (Netu) S. Sarkaria, MD, FACS Vice Chairman, Clinical Affairs Director, Robotic Thoracic Surgery Co-Director, Esophageal and Lung Surgery Institute Disclosures Speaking & Education:
More informationCharacteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Characteristics and prognostic factors of synchronous multiple primary esophageal carcinoma: A report of 52 cases Mei Li & Zhi-xiong Lin Department of Radiation
More informationSurvival, disease-free interval, and associated tumor features in patients with colon/rectal carcinomas and their resected intra-pulmonary metastases
European Journal of Cardio-thoracic Surgery 19 (2001) 908±913 www.elsevier.com/locate/ejcts Survival, disease-free interval, and associated tumor features in patients with colon/rectal carcinomas and their
More information141 Ann Thorac Surg , Aug Copyright by The Society of Thoracic Surgeons
Completion Pneumonectomy: Indications, Complications, and Results Eilis M. McGovern, M.B.B.Ch., Victor F. Trastek, M.D., Peter C. Pairolero, M.D., and W. Spencer Payne, M.D. ABSTRACT From 958 through 985,
More informationThe Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma
The Value of Adjuvant Radiotherapy in Pulmonary and Chest Wall Resection for Bronchogenic Carcinoma G. A. Patterson, M.D., R. Ilves, M.D., R. J. Ginsberg, M.D., J. D. Cooper, M.D., T. R. J. Todd, M.D.,
More informationRetroperitoneal Soft Tissue Sarcomas: Prognosis and Treatment of Primary and Recurrent Disease in 117 Patients
Retroperitoneal Soft Tissue Sarcomas: Prognosis and Treatment of Primary and Recurrent Disease in 117 Patients INGO ALLDINGER 1,2, QIN YANG 3, CHRISTIAN PILARSKY 1, HANS-DETLEV SAEGER 1, WOLFRAM T. KNOEFEL
More informationThoracic Surgery; An Overview
Thoracic Surgery What we see Thoracic Surgery; An Overview James P. Locher, Jr, MD Methodist Cardiovascular and Thoracic Surgery Lung cancer Mets Fungus and TB Lung abcess and empyema Pleural based disease
More informationAccepted Manuscript. Preoperative CEA in Patients with Colorectal Metastases Matters. Benny Weksler, MBA, MD
Accepted Manuscript Preoperative CEA in Patients with Colorectal Metastases Matters Benny Weksler, MBA, MD PII: S0022-5223(19)30068-6 DOI: https://doi.org/10.1016/j.jtcvs.2019.01.016 Reference: YMTC 14019
More informationReported Outcome Factors for Pulmonary Resection in Metastatic Colorectal Cancer
ESTS METASTASECTOMY SUPPLEMENT Reported Outcome Factors for Pulmonary Resection in Metastatic Colorectal Cancer Joachim Pfannschmidt, MD, Hans Hoffmann, MD, and Hendrick Dienemann, MD Abstract: Pulmonary
More informationExtent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer
Thoracic Cancer ISSN 1759-7706 ORIGINAL ARTICLE Extent of visceral pleural invasion and the prognosis of surgically resected node-negative non-small cell lung cancer Yangki Seok 1, Ji Yun Jeong 2 & Eungbae
More informationMEDIASTINAL STAGING surgical pro
MEDIASTINAL STAGING surgical pro Paul E. Van Schil, MD, PhD Department of Thoracic and Vascular Surgery University of Antwerp, Belgium Mediastinal staging Invasive techniques lymph node mapping cervical
More informationThe Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer
Original Article The Prognostic Value of Ratio-Based Lymph Node Staging in Resected Non Small-Cell Lung Cancer Chen Qiu, MD,* Wei Dong, MD,* Benhua Su, MBBS, Qi Liu, MD,* and Jiajun Du, PhD Introduction:
More informationClinicopathologic and prognostic factors of young and elderly patients with esophageal adenocarcinoma: is there really a difference?
Diseases of the Esophagus (2008) 21, 596 600 DOI: 10.1111/j.1442-2050.2008.00817.x Original article Clinicopathologic and prognostic factors of young and elderly patients with esophageal adenocarcinoma:
More informationMediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma*
Mediastinal Spread of Metastatic Lymph Nodes in Bronchogenic Carcinoma* Mediastinal Nodal Metastases in Lung Cancer Yoh Watanabe, M.D., F.C.C.P.; ]unzo Shimizu, M.D.; Makoto Tsubota, M.D.; and Takashi
More informationP sumed to have early lung disease with a favorable
Survival After Resection of Stage I1 Non-Small Cell Lung Cancer Nael Martini, MD, Michael E. Burt, MD, PhD, Manjit S. Bains, MD, Patricia M. McCormack, MD, Valerie W. Rusch, MD, and Robert J. Ginsberg,
More informationThe predictive accuracy of sentinel nodes mapping in the setting of pulmonary metastasectomy
DOI 10.1007/s10585-016-9834-6 RESEARCH PAPER The predictive accuracy of sentinel nodes mapping in the setting of pulmonary metastasectomy Hyun Koo Kim 1 Kwanghyoung Lee 2 Kook Nam Han 1 Jae Seon Eo 3 Sungeun
More information